Honeywell International heads into the final week of April with short sellers rebuilding positions at pace and options traders the most defensively positioned they have been in months — all against a price that has shed nearly 6% over the past month to $210.30.
The sharpest signal this week comes from short interest, which has accelerated in a way that stands out even for a name where the absolute level is modest. SI as a percentage of free float climbed to 1.86% by April 28 — up 9.2% over the week and a striking 45% above where it was a month ago. In raw terms, short positions rose from roughly 9.2 million shares in early April to nearly 11.8 million now. That is still a low absolute level, but the rate of change tells a more pointed story about how sentiment has shifted since tariff fears rattled industrials. Cost to borrow has more than doubled in a month to 0.60% — still cheap in absolute terms, but the trajectory is notable. Availability in the lending market has tightened alongside the building demand, though borrow conditions remain far from stressed.
Options positioning adds another layer of caution. The put/call ratio closed Wednesday at 0.53, almost 1.8 standard deviations above its 20-day mean of 0.44. That is the most defensively tilted the options market has been in recent months — well short of the 52-week high of 0.82 but a meaningful step up from the call-dominated posture that characterised the first quarter. Taken together with the short rebuild, the positioning picture points to investors hedging rather than pressing a directional view. The ORTEX short score at 32.3 remains in the moderate range and does not yet signal a crowded short.
The Street has absorbed Q1 results — which landed on April 23 and sent the stock down 3.1% on the day — with a round of target-price trims but no change in directional conviction. Citi cut its target from $265 to $257 while holding Buy. Barclays trimmed from $255 to $243 on a maintained Overweight. TD Cowen moved from $240 to $230, also Buy. RBC held firm at $268 with an Outperform reiteration. The pattern is consistent: analysts are marking targets lower to reflect the macro uncertainty, but none has downgraded the underlying thesis. The consensus mean target of $247.89 implies roughly 16% upside to current levels, and the RSI14 reading of 32.4 places the stock in technically oversold territory. On valuation, the forward P/E has compressed to around 19.4x — down 1.6 turns over the past 30 days — while EV/EBITDA runs near 15.4x. The dividend score ranks in the 98th percentile, reflecting a $1.19 quarterly payout that, at current prices, yields close to 2.3%.
The broader institutional picture is stable. Vanguard and BlackRock together hold close to 18% of shares outstanding, with both reporting modest additions at end-March. Columbia Management added over a million shares in Q1, one of the more active moves among the top-fifteen holders. There is no material insider buying or selling activity to flag; the recent trades on file are routine director awards and small connected sales, all scoring at the lowest significance level.
The Q1 print delivered a single day drop of 3.1%, and the next scheduled event — a Q1 2026 earnings call — is pencilled in for May 22. With short interest still climbing, the put/call ratio elevated, and price technically oversold, what to watch between now and then is whether the short rebuild continues into the print or stalls as the macro tariff backdrop evolves.
See the live data behind this article on ORTEX.
Open HON on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
